The ACC/AHA Task Force on Clinical Practice Guidelines (Task Force) continuously reviews, updates, and modifies guideline methodology on the basis of published standards from organizations including the Institute of Medicine P-1, P-2 and on the basis of internal reevaluation. Evidence Gaps and Future Research Needs e354Īppendix 1: Author Relationships With Industry and Other Entities (Relevant) e387Īppendix 2: Reviewer Relationships With Industry and Other Entities (Comprehensive) e389 Special Considerations for Catheter Ablation e349ġ8. Wearable Cardioverter-Defibrillator e348ġ1.3. Subcutaneous Implantable Cardioverter-Defibrillator e347ġ1.2. Defibrillators Other than Transvenous ICDs e347ġ1.1. Sex-Related Differences in the Risk of SCD e340ġ0.7. Older Patients With Comorbidities e339ġ0.6. VA and SCD Related to Specific Populations e338ġ0.3. Interfascicular Reentrant VT (Belhassen Tachycardia) e335ġ0. Outflow Tract and Atrioventricular Annular VA e335Ĩ.3. VA in the Structurally Normal Heart e334Ĩ.1. Specific Cardiac Channelopathy Syndromes e325Ĩ. ICD Use After Heart Transplantation e322ħ.9.1. Left Ventricular Assist Device e322ħ.7.4. HF With Preserved Ejection Fraction e321ħ.7.3. HF With Reduced Ejection Fraction e321ħ.7.2. Other Infiltrative Cardiomyopathies e320ħ.7.1. Arrhythmogenic Right Ventricular Cardiomyopathy e312ħ.6.1. Treatment of Recurrent VA in Patients With NICM e310ħ.3. Primary Prevention of SCD in Patients With NICM e309ħ.2.3. Secondary Prevention of SCD in Patients With NICM e308ħ.2.2. Treatment and Prevention of Recurrent VA in Patients With Ischemic Heart Disease e306ħ.2.1. Primary Prevention of SCD in Patients With Ischemic Heart Disease e304ħ.1.3. Secondary Prevention of SCD in Patients With Ischemic Heart Disease e301ħ.1.2. Ongoing Management of VA and SCD Risk Related to Specific Disease States e301ħ.1.1. Surgery and Revascularization Procedures in Patients With Ischemic Heart Disease e296ĥ.5.1. VA in Patients With No Apparent Structural Heart Disease e296ĥ.5. Defibrillators for Treatment of VA and SCD e295ĥ.4.2. Preventing SCD With HF Medications e295ĥ.3. Nonantiarrhythmic Medications and Therapies e294ĥ.2. Medications With Prominent Sodium Channel Blockade e290ĥ.1.5. Therapies for Treatment or Prevention of VA e290ĥ.1.1. Invasive Cardiac Imaging: Cardiac Catheterization or CT Angiography e289Ĥ.3.2. Genetic Considerations in Arrhythmia Syndromes e288Ĥ.3.1. Ambulatory Electrocardiography e286Ĥ.2.6. 12-lead ECG and Exercise Testing e286Ĥ.2.2. History and Physical Examination e284Ĥ.2.1. General Evaluation of Patients With Documented or Suspected VA e284Ĥ.1. Cellular Mechanisms and Substrates e283Ĥ. Population Subgroups and Risk Prediction e282ģ.1. Sustained VT and VF Not Associated With ACS e281Ģ.2.2. Premature Ventricular Complexes and Nonsustained VT e279Ģ.1.3. Organization of the Writing Committee e276Ģ.1.1. Customer Service and Ordering Informationġ.1.Stroke: Vascular and Interventional Neurology.Journal of the American Heart Association (JAHA).Circ: Cardiovascular Quality & Outcomes.Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).

Svt with ivcd